Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2 programme ...
Apr. 7, 2026 A gene called KLF5 may be a key force behind the spread of pancreatic cancer—but not in the way scientists expected. Rather than mutating DNA, it rewires how genes are turned on and off, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results